aiwiki.page
English
Health / Diseases & Symptoms / chronic-myeloid-leukemia

Chronic Myeloid Leukemia

Chronic myeloid leukemia is a BCR::ABL1-driven blood cancer whose treatment with targeted kinase inhibitors has transformed survival and enabled treatment-free remission in selected patients.

37 keywords12 linked from5 not yet writtenWritten by AI
CancerBone MarrowPhiladelphia Chr…Precision Medici…LeukemiaHydroxyureaRandomized Contr…IncidenceChronic My…

Chronic myeloid leukemia (CML) is a cancer of blood-forming stem cells characterized by the acquired fusion gene BCR::ABL1. It usually begins in the bone marrow and produces excessive numbers of granulocytes, a group of white blood cells that includes neutrophils, eosinophils, and basophils. Its defining genetic abnormality most often arises from an exchange of material between chromosomes 9 and 22, producing the Philadelphia chromosome. Unlike many acute leukemias, CML commonly presents with substantial preservation of blood-cell maturation.

CML has a distinctive place in the history of precision medicine. Identification of its chromosome abnormality, discovery of the resulting continuously active signaling enzyme, and development of drugs that inhibit that enzyme established a direct connection between a cancer-driving genetic change and effective treatment. Since the introduction of tyrosine kinase inhibitors, many people diagnosed in chronic phase have achieved long-term disease control, and survival in well-treated populations can approach that of the general population.

The disease nevertheless requires precise molecular diagnosis and prolonged assessment. Its clinical behavior depends on disease phase, genetic evolution, response to treatment, drug tolerability, and continuity of care. Some patients maintain remission after stopping treatment under structured monitoring, whereas resistant disease and progression to blast phase remain major clinical challenges.

Historical development and epidemiology

Descriptions published independently by John Hughes Bennett and Rudolf Virchow in 1845 helped establish leukemia as a recognizable disease. The distinction between chronic myeloid and other leukemias emerged gradually as blood microscopy and marrow examination improved. For much of the twentieth century, treatment could reduce blood counts and symptoms but usually could not prevent eventual progression. Busulfan and later hydroxyurea were used for cytoreduction; interferon alfa subsequently produced meaningful cytogenetic responses in a minority of patients.

In 1960, Peter Nowell and David Hungerford reported a consistently small chromosome in cells from patients with CML. It became known as the Philadelphia chromosome, after the city in which it was discovered. Janet Rowley demonstrated in 1973 that this abnormality resulted from a reciprocal translocation rather than a simple deletion. Work during the following decade identified the involvement of the ABL1 and BCR genes. These discoveries made CML one of the first human cancers in which a recurrent chromosome change was connected to a specific molecular mechanism.

The development of imatinib transformed treatment. Clinical studies led by investigators including Brian Druker demonstrated that inhibition of the BCR::ABL1 kinase could produce marked responses. Imatinib received its first United States regulatory approval in 2001. The subsequent IRIS randomized controlled trial established its superiority over interferon alfa plus low-dose cytarabine for newly diagnosed chronic-phase disease. In long-term follow-up of the group originally assigned to imatinib, estimated overall survival at 10 years was 83.3%; interpretation also requires recognition of treatment changes and incomplete long-term follow-up.

CML accounts for approximately 15% of adult leukemias in many Western populations. Its annual incidence is generally around 1–2 cases per 100,000 people, although estimates vary by population, age structure, and cancer-registration methods. Incidence rises with age, and men are affected somewhat more often than women. In the United States, the median age at diagnosis is approximately the mid-60s. Younger median ages reported in some countries partly reflect differences in population structure and ascertainment.

Most cases have no identifiable external cause. High-dose ionizing radiation is an established risk factor, but most patients have no such exposure history. CML is generally not inherited: the defining alteration is acquired in blood-forming cells rather than present throughout the body from conception. Because treatment has greatly prolonged survival, prevalence has increased even where incidence has remained relatively stable, creating a growing population requiring long-term molecular testing and access to medication.

Molecular origin and leukemic stem cells

CML originates in a hematopoietic stem cell capable of generating several blood-cell lineages. The characteristic translocation is written t(9;22)(q34;q11.2)t(9;22)(q34;q11.2). It brings part of ABL1 on chromosome 9 next to part of BCR on chromosome 22. The resulting shortened chromosome 22 usually carries the BCR::ABL1 fusion. A minority of cases have variant rearrangements involving additional chromosomes or cryptic fusions that are not apparent on conventional chromosome examination.

ABL1 normally encodes a tightly regulated enzyme involved in cellular signaling. Fusion to BCR disrupts that regulation and promotes persistent tyrosine kinase activity. The fusion protein activates signaling pathways including RAS–MAPK, PI3K–AKT, and JAK–STAT. These signals increase proliferation, reduce programmed cell death, alter adhesion to the marrow environment, and favor expansion of the leukemic clone. The abnormality is therefore not simply a diagnostic marker; it is the principal disease-driving lesion and the target of treatment.

Most patients express a BCR::ABL1 protein of approximately 210 kilodaltons, usually produced by the e13a2 or e14a2 transcript. Other transcripts occur less often. The approximately 190-kilodalton form is more commonly associated with Philadelphia-positive acute lymphoblastic leukemia but can occur in CML. Identifying the transcript at diagnosis matters because standard molecular assays do not detect or quantify every unusual fusion equally well. Transcript structure also illustrates why the presence of BCR::ABL1 alone does not determine the clinical category without consideration of the blood, marrow, and disease history.

During chronic phase, leukemic progenitors retain considerable capacity to mature. This explains why the blood contains large numbers of relatively mature granulocytes together with earlier myeloid forms, rather than consisting predominantly of immature blasts. BCR::ABL1 can also be found in other cell lineages, consistent with its origin in a multipotent stem cell. Additional genetic and chromosomal changes may accumulate over time, contributing to loss of differentiation and progression.

A central biological limitation of kinase inhibition is persistence of leukemic stem cells. Some primitive cells survive despite effective suppression of BCR::ABL1 signaling, supported by quiescence, alternative survival pathways, and interactions with the marrow microenvironment. Consequently, an extremely low or undetectable blood transcript level does not prove that every leukemic cell has been eliminated. Research into stem-cell persistence, cellular metabolism, and immune control seeks to explain both relapse after treatment withdrawal and durable remission without continued medication.

Clinical presentation and disease phases

Many patients are diagnosed after an incidental complete blood count shows leukocytosis. Others have gradually developing fatigue, reduced exercise tolerance, weight loss, night sweats, or abdominal fullness. Enlargement of the spleen may cause early satiety or discomfort beneath the left ribs because the organ accumulates blood cells and participates in blood-cell production outside the marrow. Symptoms can be mild even when the white-cell count is markedly elevated.

The characteristic blood picture includes granulocytes at multiple stages of maturation, often with prominent myelocytes, increased basophils, and sometimes increased eosinophils. Platelet counts may be normal or elevated, and mild anemia is common. Some patients present predominantly with thrombocytosis rather than striking leukocytosis. Elevated lactate dehydrogenase and uric acid reflect increased cell production and turnover, but neither finding is specific for CML.

Occasionally, extreme leukocytosis is accompanied by leukostasis, in which interactions between circulating cells and small vessels impair blood flow. Neurological symptoms, visual disturbances, respiratory compromise, or priapism can occur, although leukostasis is less frequent in chronic-phase CML than in acute leukemias at comparable white-cell counts. Bleeding or thrombosis can also occur. Infection is not usually the dominant initial feature of otherwise uncomplicated chronic-phase disease, because many circulating cells retain functional maturation.

Historically, CML has been divided into chronic phase, accelerated phase, and blast phase. Classification systems now differ. The fifth edition of the World Health Organization classification treats CML principally as a biphasic disease—chronic phase and blast phase—and does not retain accelerated phase as a separate category. The 2022 International Consensus Classification retains accelerated phase, including features such as 10–19% blasts in blood or marrow, marked basophilia, and specified additional clonal chromosome abnormalities. Thus, a phase label must be interpreted in relation to the classification used.

Blast phase is generally defined by at least 20% blasts in blood or marrow, or by an extramedullary proliferation of blasts. The blasts may be myeloid or lymphoid, most often B-lineage in the latter group. Increasing blasts, worsening cytopenias unrelated to treatment, enlarging spleen, or new chromosomal abnormalities can indicate progression. Without effective disease-modifying therapy, chronic-phase CML historically evolved into advanced disease over several years; contemporary kinase inhibition substantially reduces this risk, especially when a durable molecular response is achieved.

Diagnostic confirmation and baseline risk assessment

The diagnosis of CML requires demonstration of BCR::ABL1 in the appropriate clinical and hematological setting. An elevated white-cell count alone is insufficient. Initial evaluation commonly combines a blood count and differential, examination of a peripheral blood smear, marrow assessment, chromosome analysis, and molecular testing. These methods answer different questions: whether the defining fusion is present, how the marrow is organized, which disease phase is present, and whether additional abnormalities already exist.

A marrow aspirate permits assessment of blast percentage and conventional cytogenetics. A marrow biopsy provides information about cellularity, megakaryocytes, and fibrosis, particularly when an aspirate is inadequate or the presentation is atypical. Typical chronic-phase marrow is markedly cellular, with expanded granulopoiesis and often small, hypolobated megakaryocytes. Conventional chromosome analysis can identify the Philadelphia chromosome and additional clonal abnormalities, such as an extra Philadelphia chromosome, trisomy 8, or isochromosome 17q.

Fluorescence in situ hybridization detects juxtaposition of BCR and ABL1 sequences and can identify some cryptic rearrangements. Reverse-transcription polymerase chain reaction detects the fusion transcript and establishes its type. Quantitative testing then provides the basis for subsequent molecular monitoring. A negative routine assay does not exclude an unusual fusion if cytogenetic or clinical findings remain strongly suggestive; specialized assays may be needed for atypical transcripts.

The differential diagnosis includes reactive leukocytosis, other myeloproliferative neoplasms, chronic myelomonocytic leukemia, and myelodysplastic/myeloproliferative neoplasms with neutrophilia. Infection-related leukemoid reactions may produce a left shift but lack the defining BCR::ABL1 fusion. CML presenting with blast proliferation must also be distinguished from BCR::ABL1-positive acute leukemia. The distribution of the fusion among cell lineages, prior blood counts, basophilia, splenomegaly, marrow morphology, and other genetic findings help resolve difficult cases.

Baseline prognostic models estimate the probability of adverse outcomes but do not replace response assessment. The historical Sokal score uses age, spleen size, platelet count, and blood blast percentage. The EUTOS long-term survival score, or ELTS score, was developed in the kinase-inhibitor era to estimate CML-related mortality using the same broad clinical variables with different weighting. Additional chromosome abnormalities and high-risk disease features provide further context. Baseline assessment also documents cardiovascular, pulmonary, hepatic, and renal conditions because these can influence the safety of different treatments independently of leukemia risk.

Targeted drug treatment

The foundation of chronic-phase treatment is a tyrosine kinase inhibitor directed against BCR::ABL1. Most established agents bind the kinase domain near its adenosine triphosphate binding site, preventing phosphorylation of downstream proteins. This suppresses the competitive advantage of the leukemic clone and permits normal blood formation to recover. Blood counts often improve before the full cytogenetic and molecular effects become apparent.

Imatinib is the first-generation agent and has the longest clinical follow-up. Second-generation inhibitors include dasatinib, nilotinib, and bosutinib. Compared with imatinib, these agents generally produce faster and deeper molecular responses in newly diagnosed chronic-phase disease, although differences in overall survival have been less clear because effective subsequent treatments are available. Drug selection therefore depends not only on response probabilities but also on toxicity profiles, existing illnesses, drug interactions, availability, and the potential importance of achieving a deep response.

The agents are not interchangeable in their adverse effects. Imatinib commonly causes fluid retention, muscle cramps, gastrointestinal symptoms, and cytopenias. Dasatinib is associated with pleural effusions and, less commonly, pulmonary arterial hypertension. Nilotinib can cause metabolic abnormalities, QT-interval prolongation, and arterial vascular events. Bosutinib frequently causes diarrhea and can produce hepatic enzyme abnormalities. These associations influence clinical selection and follow-up rather than establishing a single best drug for every patient.

Ponatinib inhibits BCR::ABL1 carrying the T315I mutation, which confers resistance to several earlier inhibitors. Its use is limited by clinically important arterial occlusive events, hypertension, and other toxicities; response-adapted dosing strategies have been investigated to balance activity and risk. Asciminib acts differently, binding the ABL myristoyl pocket rather than the ATP site. This allosteric mechanism provides an additional treatment option, with approved indications varying by jurisdiction and changing as evidence develops. Asciminib also has distinctive resistance mechanisms and can cause cytopenias, pancreatic toxicity, and vascular adverse events.

Hydroxyurea may be used temporarily to reduce very high counts while diagnostic confirmation or definitive treatment is being arranged, but it does not replace BCR::ABL1-directed therapy. Interferon alfa retains a role in selected circumstances, including some pregnancy settings. In chronic-phase disease responding well to a kinase inhibitor, conventional intensive chemotherapy is not ordinarily part of routine treatment. The therapeutic objective is sustained suppression of the leukemic clone with acceptable toxicity, documented by standardized molecular testing rather than blood-count normalization alone.

Measuring response and interpreting molecular milestones

Response is assessed at several biological levels. A complete hematological response means that blood counts and the differential have normalized, immature circulating myeloid cells have resolved, and clinically significant splenic enlargement has disappeared. A complete cytogenetic response means that no Philadelphia-positive metaphases are detected in an adequate conventional marrow chromosome examination. Molecular response measures BCR::ABL1 messenger RNA in blood and can detect residual disease far below the sensitivity of microscopy or chromosome analysis.

For common transcripts, results are reported on the International Scale. The measured BCR::ABL1-to-reference-gene ratio is calibrated to an internationally standardized baseline, with 100% representing the historical standardized baseline rather than the percentage of blood cells that are leukemic. A major molecular response, or MMR, corresponds to BCR::ABL1 of 0.1%0.1\% or less on this scale. Deeper responses include MR4 at 0.01%0.01\% or less and MR4.5 at approximately 0.0032%0.0032\% or less. These correspond to reductions of 4 and 4.5 logarithms from the standardized baseline.

Widely used response frameworks assess BCR::ABL1 at approximately 3, 6, and 12 months after treatment begins. Common favorable targets are no more than 10% at 3 months, no more than 1% at 6 months, and no more than 0.1% at 12 months. These thresholds arose from associations between early molecular decline and later outcomes. Their application is contextual: a result near a boundary, a treatment interruption, a falling transcript trajectory, and a persistently rising level do not carry identical implications.

Molecular testing is commonly performed about every three months early in treatment, with intervals individualized once response is stable. An unexpected rise is assessed alongside previous results, laboratory variation, dose changes, missed treatment, and drug interactions. Loss of an established response is more informative than a small isolated fluctuation. Blood counts remain necessary because molecular testing does not identify cytopenias, organ toxicity, or every form of disease evolution.

“Undetectable” BCR::ABL1 is not synonymous with absence of leukemia. Its meaning depends on RNA quality, assay sensitivity, and the number of reference-gene transcripts successfully measured. A sample with few evaluable cells cannot establish a deep response merely because the fusion transcript was not detected. Standardization, laboratory quality assurance, and appropriate methods for atypical transcripts are therefore essential. Molecular response is a powerful biomarker, but its interpretation depends on both analytical performance and the patient’s longitudinal clinical course.

Resistance, progression, and transplantation

An inadequate response can arise through several mechanisms. Apparent resistance may reflect reduced drug exposure caused by interruptions, intolerance, malabsorption, or interactions with other medicines. Some inhibitors depend on gastric acidity for absorption, and many are affected by hepatic drug-metabolizing enzymes. Distinguishing insufficient exposure from biological resistance is important because changing drugs does not automatically correct an underlying exposure problem.

Biological resistance often involves a mutation in the ABL1 kinase domain that reduces drug binding. T315I is a well-known example, but other substitutions have differing sensitivity patterns across available inhibitors. Sequencing is used in appropriate settings of treatment failure, loss of response, or progression to help characterize resistance. More sensitive sequencing methods can identify smaller mutant subclones than conventional Sanger sequencing. Compound mutations occurring within the same BCR::ABL1 molecule can create more complex resistance patterns.

Resistance can also develop without a detectable kinase-domain mutation. Increased BCR::ABL1 expression, alternative signaling pathways, altered drug transport, and acquisition of additional genetic lesions may contribute. Additional chromosome abnormalities in the Philadelphia-positive clone can signal clonal evolution. Disease progression is associated with broader disruption of differentiation and growth control, including alterations affecting tumor suppressors, transcription factors, and chromatin regulation. Once blast phase develops, inhibiting BCR::ABL1 alone is usually insufficient for durable control.

Treatment of blast phase depends partly on lineage. Myeloid blast phase may be treated with a potent kinase inhibitor combined with an acute myeloid leukemia–type regimen or a lower-intensity alternative, depending on clinical circumstances. Lymphoid blast phase may involve an acute lymphoblastic leukemia–type approach, and selected regimens incorporate antibody-based therapy. The objective is often to restore a second chronic phase and proceed to allogeneic hematopoietic stem-cell transplantation when feasible. Outcomes are generally better when transplantation occurs before uncontrolled advanced disease.

Allogeneic transplantation was the principal potentially curative treatment before kinase inhibitors and remains important for selected resistant or advanced cases. Donor immune cells can eliminate residual leukemia through the graft-versus-leukemia effect. This benefit is balanced against conditioning toxicity, infection, organ injury, and graft-versus-host disease. Transplant outcomes depend on disease phase, response before transplantation, age, comorbidities, donor characteristics, and other factors. Its role has narrowed in routine chronic-phase care but remains substantial where successive targeted treatments fail.

Treatment-free remission

Treatment-free remission describes sustained disease control after stopping a tyrosine kinase inhibitor. It is distinct from stopping treatment because of toxicity without an established remission strategy, and it does not establish that all leukemic cells have been eradicated. The concept emerged from observations that some patients with prolonged deep molecular responses remained stable after withdrawal, challenging the earlier assumption that every patient would require uninterrupted lifelong therapy.

Prospective studies, including STIM and EURO-SKI, established the feasibility of structured discontinuation in selected chronic-phase patients. Across studies with differing eligibility criteria, approximately 40–60% of participants have remained free of treatment over the reported follow-up periods. Selection commonly includes several years of kinase-inhibitor exposure, a sustained deep molecular response, access to a sufficiently sensitive standardized assay, and the ability to undergo frequent follow-up. Exact criteria differ among professional guidelines and study protocols.

Most molecular recurrences occur within the first six months after stopping, although later relapses occur. Loss of MMR is widely used as the threshold for restarting therapy. In closely monitored studies, the great majority of patients who restarted treatment regained molecular response. This favorable experience depends on timely testing and treatment resumption; it cannot be extrapolated to unmonitored discontinuation. Progression during a properly supervised treatment-free remission attempt has been very uncommon but is not considered impossible.

Longer duration of treatment and longer duration of deep molecular response are associated with a greater probability of successful discontinuation. No single routine test reliably determines in advance who will remain treatment-free. Research has examined immune-cell populations, residual leukemic stem cells, transcript type, and more sensitive molecular assays. Persistent immune surveillance may help contain a small residual clone in some patients, but the relative contributions of immune control and stem-cell biology remain incompletely defined.

A withdrawal syndrome can follow discontinuation, most often involving new or worsening musculoskeletal pain. It usually occurs during the early months and is separate from molecular recurrence. Treatment-free remission may reduce medication burden, chronic adverse effects, and cost, but frequent early blood testing remains necessary and long-term surveillance continues. It also has implications for reproductive planning because several kinase inhibitors carry fetal risks. The scientific question is therefore broader than whether a drug can be stopped: it concerns the conditions under which residual leukemia remains controlled without continuous kinase inhibition.

Long-term outcomes, special populations, and access to care

For patients diagnosed in chronic phase who receive effective treatment and maintain response, the outlook differs profoundly from the historical natural history of CML. Population studies from settings with broad access to kinase inhibitors have documented marked gains in life expectancy, with some treated groups approaching general-population survival. Outcomes are not uniform, however. Advanced phase at diagnosis, resistant disease, serious comorbidities, and limited access to treatment or molecular monitoring remain associated with worse results.

Long survival makes cumulative toxicity and quality of life central outcomes. Persistent fatigue, gastrointestinal symptoms, cramps, fluid retention, and skin effects may continue despite excellent leukemia control. Vascular, pulmonary, metabolic, renal, and hepatic complications vary by drug and patient characteristics. Dose reduction has been studied in patients with stable responses, illustrating the distinction between the maximum tolerated dose and the dose sufficient for sustained disease suppression. Any interpretation of such studies depends on continued molecular surveillance and the population examined.

CML is uncommon in children and adolescents. Pediatric disease is driven by the same defining fusion, but presentation may include particularly high white-cell counts and marked splenomegaly. Long exposure to kinase inhibitors during growth raises issues involving linear growth, bone metabolism, endocrine development, and adherence over adolescence. Adult prognostic models and treatment-free remission evidence are not automatically transferable to pediatric populations, for which disease-specific expertise and long-term follow-up data are especially important.

Pregnancy creates distinct treatment constraints because several kinase inhibitors can harm embryonic or fetal development. Risks vary by agent and timing of exposure; dasatinib, for example, can cross the placenta and has been associated with serious fetal complications. Published management approaches may involve treatment interruption, close blood and molecular monitoring, interferon alfa, or selected cytoreductive measures according to disease status and gestational stage. Maternal exposure and paternal exposure are different clinical questions and have different evidence bases. Breastfeeding during kinase-inhibitor treatment is also limited by potential drug transfer into milk.

The effectiveness of modern treatment depends on delivery through functioning health systems. Generic imatinib has lowered medication costs in many countries, but access to newer agents, reliable molecular assays, mutation analysis, and transplantation remains uneven. Out-of-pocket costs and interruptions in drug supply can undermine otherwise effective treatment. Because CML is now often managed over decades, outcome measurement increasingly includes sustained access, patient-reported symptoms, work and family participation, and the practical burden of repeated testing alongside conventional survival and response endpoints.